Press Room

Press Release / Aug 23, 2012

Hovione Announces the Appointment of Conrad Winters

Hovione Announces the Appointment of Conrad Winters, PhD as Drug Product Development Director

Loures, Portugal, 23rd August 2012 - Hovione announced the appointment of Dr. Conrad Winters as Director, Drug Product Development. Dr. Winters was previously with Merck in USA and Canada and most recently with Xenon Pharmaceuticals Inc., where he held the position of Senior Director, Compound Properties Group.

“We are very pleased to welcome Dr. Winters to Hovione. His experience in particle engineering, solubilisation, drug product development, scale up and commercialization will enable us to solve our customers’ most challenging problems”, said Dr. Thomas Eisele, Vice President Corporate Research & Development.

“I am delighted to join the strong team at Hovione. Already the recognized world leader in pharmaceutical spray drying, I am looking forward to leading the team in developing complimentary technologies to enable Hovione to offer customers’ integrated solutions for any molecule”, said Dr. Winters.

Dr. Winters is a Senior Director with 18 years experience in the pharmaceutical industry with a focus on managing the development of compounds from lead candidate optimization through to NDA submission and commercialization. He has much experience in rational formulation design, based on fundamental understanding of material properties and the adaptation of particle properties to effect improved bioperformance. Dr. Winters has led cross functional global teams charged with the development of priority new chemical entities. He has contributed to and prepared documentation in support of many successful regulatory submissions.

Dr. Winters is a member of the American Association of Pharmaceutical Scientists and of the Royal Pharmaceutical Society of Great Britain. He is author of four patents, ten papers and is a frequent speaker at international conferences. He trained as a pharmacist at the Bradford University, Bradford, UK, and holds a PhD in Pharmaceutical Technology from the same University.

About Hovione

Hovione is a global company with over 50 years’ experience in Active Pharmaceutical Ingredient and Drug Product Intermediate development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. Hovione offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024